MITF levels were also significantly higher in advanced clinical stages, with melanomas in stages 0–IIa showing a median expression of 14% (95% CI: 2%–52%) compared to 47% (95% CI: 14%–87%) in stages III–IV (H ═ 8.41, P ═ 0.03). Here, MITF is linked to melanoma.